On October 6, 2026, OKYO Pharma Ltd announced a significant milestone in its clinical development by enrolling the first patients in the Phase 3 NEPTUNE trial for urcosimod, aimed at treating neuropathic corneal pain (NCP). This event is crucial as it marks the company's advancement towards potentially offering the first FDA-approved therapy for this debilitating condition.
OKYO Pharma, a clinical-stage biopharmaceutical company, specializes in developing innovative therapies for neuropathic corneal pain and other anterior segment eye diseases. The company is listed on the Nasdaq under the ticker symbol OKYO. The recent filing, dated October 6, 2026, follows a series of disclosures, including multiple 6-K forms that highlight the company's ongoing efforts and developments.
The filing states, "On October 6, 2026, OKYO Pharma LTD (the 'Company') issued this 6-K announcing first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP)." This announcement indicates the initiation of a pivotal study that could significantly impact the treatment landscape for patients suffering from NCP.
The NEPTUNE trial is designed to evaluate urcosimod as a first-in-class treatment for neuropathic corneal pain, a condition that currently lacks FDA-approved therapies. Dr. Melissa Toyos, a leading ophthalmologist, has enrolled the first patients at Toyos Clinic in Nashville, TN. The trial will assess the efficacy of urcosimod through various endpoints, including changes in ocular pain and quality-of-life scores.
This development may affect a wide range of stakeholders, including patients suffering from NCP, healthcare providers seeking effective treatment options, and competitors in the biopharmaceutical industry. The trial's success could position OKYO as a leader in the biological products sector, particularly in the field of ocular therapies.
As the NEPTUNE trial progresses, further updates and filings are anticipated. The filing does not specify what happens next, but the initiation of this pivotal trial is a promising step for OKYO Pharma in addressing a significant unmet medical need.